Data reported here indicates the presence of a dysregulation of the endocannabinoid system (ECS) in terms of changed expression of cannabinoid CB1 and CB2 receptors or altered levels of endogenous ligands such as AEA and 2-AG in animal models of schizophrenia (SCZ) as well as in schizophrenic subjects. Thus, due to the limited efficacy of actual antipsychotics, ECS modulation may provide a novel therapeutic target for the treatment of psychiatric disorders. The state of art concerning preclinical and clinical data on cannabinoids with respect to the modulation of positive, negative symptoms and cognitive deficits of SCZ is discussed in this chapter. Furthermore, this chapter will highlight the potential of phytocannabinoids, including cannabidiol as therapeutic agents for SCZ treatment.
Role of the endocannabinoid system in schizophrenia: From preclinical to human evidence
Di Martino S.Primo
Writing – Original Draft Preparation
;Drago F.;Micale V.
Ultimo
2026-01-01
Abstract
Data reported here indicates the presence of a dysregulation of the endocannabinoid system (ECS) in terms of changed expression of cannabinoid CB1 and CB2 receptors or altered levels of endogenous ligands such as AEA and 2-AG in animal models of schizophrenia (SCZ) as well as in schizophrenic subjects. Thus, due to the limited efficacy of actual antipsychotics, ECS modulation may provide a novel therapeutic target for the treatment of psychiatric disorders. The state of art concerning preclinical and clinical data on cannabinoids with respect to the modulation of positive, negative symptoms and cognitive deficits of SCZ is discussed in this chapter. Furthermore, this chapter will highlight the potential of phytocannabinoids, including cannabidiol as therapeutic agents for SCZ treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
